We can’t show the full text here under this license. Use the link below to read it at the source.
Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know
Glucagon-like peptide-1 receptor agonists in fatty liver disease, obesity, and diabetes: important information for liver specialists
AI simplified
Abstract
Liraglutide and semaglutide led to histological resolution of in ~40% to 60% of patients.
- GLP-1 receptor agonists significantly lower glucose levels and promote body weight loss in large trials involving type 2 diabetes.
- In individuals with obesity without type 2 diabetes, liraglutide and semaglutide are associated with sustained body weight reduction.
- Liraglutide reduced metabolic dysfunction, insulin resistance, and lipotoxicity in a phase II trial focused on NASH.
- Statistically significant effects of GLP-1 receptor agonists on fibrosis in NASH have not been confirmed.
- Gastrointestinal and gallbladder-related adverse events are associated with GLP-1 receptor agonists, possibly linked to weight loss.
- Meta-analyses show no increased risk of acute pancreatitis, pancreatic cancer, or other malignancies with GLP-1 receptor agonists.
AI simplified
Key numbers
39%
Resolution Rate Increase
Resolution of in patients treated with liraglutide vs. placebo.
14.9%
Weight Loss with Semaglutide
Mean percentage weight loss in adults with obesity treated with semaglutide vs. placebo.